RecruitingNCT07059936
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enrollment
350 participants
Start Date
Jul 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patients were treated for hepatocellular carcinoma in Wuhan Union Hospital from July 2025 to July 2026;
- Aged \> 18 years old;
- At least one CT scan or MR scan before treatment;
- Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.
Exclusion Criteria4
- Poor image quality;
- Incomplete clinical data or loss of follow-up;
- Presence of another primary malignancy other than liver cancer;
- Unclear pathological diagnosis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07059936
Related Trials
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
NCT070522531 location
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT0717665051 locations
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
NCT074693196 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483122 locations
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT0729107645 locations